ALLARITY THERAPEUTICS INC (ALLR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.98-9.64%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ALLR
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(16.7) + peer(0.2*3.2) + term(0.0) → 6.48% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
in 8 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 14, 2026, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On March 31, 2026, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…
Results of Operations and Financial Condition. On May 9, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
Results of Operations and Financial Condition. On March 31, 2025, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024 and forward-looking statements relating to its first quarter of 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the…
Results of Operations and Financial Condition On November 14, 2024, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2024 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On May 14, 2024, the Company issued a press release announcing its financial results for its fiscal quarter ended March 31, 2024 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On May 14, 2024, Allarity Therapeutics, Inc. issued a press release announcing its financial results for its fiscal quarter ended March 31, 2024 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On March 8, 2024, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain financial and operational information for its fiscal year ended December 31, 2023 and provided a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On November 15, 2022, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain financial and operational information for its third fiscal quarter ended September 30, 2022 . The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On October 11, 2022, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, certain financial and operational information for its second fiscal quarter ended June 30, 2022 and announcing that it had regained compliance with Nasdaq listing requirements. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The operational highlights regarding the Company’s ne…
Results of Operations and Financial Condition. The Company’s information regarding its financial statements for the three and six months ended June 30, 2022, furnished under
above is incorporated herein by reference. The information reported under Items 2.02 and 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, is being “furnished” and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regard…
Results of Operations and Financial Condition. On May 16, 2022, the Company issued a press release announcing, among other things, limited financial and operational information for its fourth quarter and full fiscal year ended December 31, 2021 and provided a corporate update including certain forward-looking performance estimates and anticipated milestones in 2022 (the “Earnings Release”). On May 18, 2022, the Company issued a press release announcing a correction of a typographical error in…
Results of Operations and Financial Condition. On May 16, 2022, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, limited financial and operational information for its fourth quarter and full fiscal year ended December 31, 2021 and provided a corporate update including certain forward-looking performance estimates and anticipated milestones in 2022. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8…